
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly is a leader in the biopharmaceutical industry with a diverse portfolio of drugs focused on key therapeutic areas including neuroscience, cardiometabolic, cancer, and immunology. The company's strong performance and portfolio diversification suggest continued success, particularly in the oncology and obesity spaces, where the company's products have shown strong growth. Management's commitment to research and development gives confidence in future pipeline developments and the potential for even more growth. Despite some challenges in the retail market in which it operates, Eli Lilly has demonstrated resilience and is positioned for further success in the industry.
Bears say
Eli Lilly is facing multiple downside risks as potential pricing and rebate pressure, slower Rx trajectory of tirzepatide, and a worse-than-expected launch of Forglipron could all impact the company's financial performance. Additionally, the company's pipeline products may not perform as well as expected, and highest costs may decrease earnings. Despite expecting a guidance raise, the analyst also notes that it may not be as significant as previous increases, and points to Medicare expansion and global opportunities as potential positives. However, with a 30x P/E multiple, this outlook reflects a negative sentiment towards the company's prospects.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares